Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe he is too busy buying up shares to reply!
Just a few thoughts as I continue to get my head around Dyadic. Certainly Mark is working all the bases to raise awareness of Dyadic through collaborations with small, medium and large companies for equity, milestone and royalty payments; presenting at many industry conferences; using CRO's such as VTT to continue to improve results and avoid the high capital costs of doing it themselves; and paying for analyst coverage such as from Zacks. The objective being to sell the technology to big pharma just as they did when they sold the industrial technology business to Dupont in November of 2015 for $75 million.
But note that the price of DYAI declined from over $2 in January of 2013 to roughly $1 by the end of October of 2015. It then rose to about $1.80 when Dupont bought the technology in November. So Dupont appears to have gotten quite a bargain as there was no interest in the stock. They would likely have paid more if individual investors (retail) and institutions had been more aware of Dyadics prospects. And I think this is the case right now. We need more analyst coverage to increase interest and ownership in these two areas. Also, a low float can sometimes be a negative as it is more difficult for institutions to get a large enough position at a reasonable price.
What can Dyadic do to mitigate this? Perhaps taking a relatively large ownership position in a CRO or some other company with complementary technology and issuing stock through a group of investment houses to pay for it. If this opportunity exists, it would then give them the analyst coverage they need, a larger float and a more diversified company. Thoughts?
Yes, raising money through investment houses gets you analyst coverage. And without it you do not get retail investment since the pump is missing except for Mark's efforts at industry conferences. His family owns 24%, institutional investors another 6%, I believe. So that is 30%. 70% is still up for grabs. Who knows how much big pharma already owns or how the 6% would vote if an offer is made by big pharma for the company.
Interesting link ronpopeil. I think you are right that retail investors do not fully appreciate the importance of C1 and the glyco news. But I imagine big pharma does. I would like to see analysts get excited and start recommending this stock. I hope Mark is working on them diligently. Dyadic does not appear to have an dedicated investor relations person. This might then get retail investors bidding up the price and forcing big pharma to pay up more to ultimately take out Dyadic. This is my dream scenario. If this doesn't happen, I am afraid big pharma will still buy out Dyadic, but at a much lower price.
DYAI stock price has reached the bottom of its sideways trading channel. Will it bounce up as before? Especially considering their recent announcement about achieving human like glycan structures from its engineered C1 cell line, it seems very likely.
Mark Emalfarb will be presenting at the BIO International Convention 2019 in Philadelphia which runs today through June 6. Not sure if he is presenting today but this is a very large convention. The convention website states “The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.
Maybe someone likes what they see...
Matt Jones, Managing Director for Business Development & Licensing remarked during the conference call "You are seeing some of the fruits of our labour come true now. We are just beginning what we think is the tip of the iceberg." I tend to agree with him. Look at all the milestones they have hit or exceeded. Incredible! Good job!!
I am glad Dyadic held its price as well as it did this first day. It has been my experience that up-listings, as with ipo’s, tend not to do well initially. Could have something to do with investor optimism being baked in ahead of the event. If we hang in here, I think it will speak volumes as to future price appreciation.
Thanks Tykundegex, Paullee, ronpopeil, TheMonolith and $PistolPete$ et al!
I am a big believer in this stock and have been in it since sub $2.00.
I very much enjoy your contributions to this board. We are early as not many other posters yet. I think that will change this year. The high cost of biologics has to come down if we are to continue to bring new products to commercialization. The FDA and pharmaceutical companies know this and are looking for a new gene expression standard. We have a very good chance of becoming that new standard! Good luck guys!!
Thanks for all your dd junkHustler. I agree that this stock has serious legs. Rob McWirter of Selective Asset Management Inc. likes it as well. He has a great track record and is widely followed. Second largest holding for his family. A change in the political parties in the US in 2020 to an administration that is more proactive to reducing carbon emissions could also make a huge difference. A reduction in reliance on fossil fuels globally is baked in. It's only a matter of time!
Wow. Lots of thoughts in this post!
When you refer to a cotton module, is this one marked lot that can be matched to a particular origin (field) and a specific blockchain identifier?
If all cotton sent to a particular gin has been marked by APDN, I would think their testing should be able to provide a list of ALL sources.
I agree that marking needs to be done ultra cheaply. This is not a high margin game but rather a high volume one.
I also agree whole-heartedly that testing needs to be conveniently done in the workplace (not a lab). I noticed in one company announcement for package marking APDN stated that their testing would simply require a swab of their marker, then snipping off the end of the q-tip, and putting multiples of these in a device for testing. This sounds way too onerous to me. What factory or distribution centre would find this convenient? I would rather see a handheld device that you simply point at the product and it quickly provides a readout and/or a printout of the products provenance.
Thanks again for an interesting post!
Your alias was born in August and already you are a disgruntled investor? Not likely. This is an investor's forum as Parkmart mentioned. Management doesn't turn you on? Then move along HareBrain. Nothing here for you.
Ha! You are funny, SOL ($hit Outta Luck?). Insights? Why yes. Quit worrying about the short term (unless you're 97!). By the way, the theoretical max life expectancy is about 120 years (Hayflick limit). This company has major players kicking the tires. That, of course, means they like the potential. No news means they are still considering. It's easy to get negative with no news. Guard against it. Still a very good odds game and the company continues to chip away, abeit too slowly for some. Huge market and the counterfeiters are winning!
I agree with HANUMAN on your childlish abbreviations. Very tiring. And why always ask other people to contact the company. What about you?
Your paltry command of the English language is only usurped by your lack of investment knowledge, McSmartey. But you do try to be funny and provide comedic relief. And people genuinely seem to like having you around. Hang in there buddy!
Thanks abew4me. Looks like the reset for Sabby’s warrants would be the price per share of any new offering rather than the higher price of any attached warrants assuming the new issue is done below $2. If the pp is done above $2, then no impact. So Sabby’s warrants continue to hold their original value relative to any new issue. Is that the way you see it?
If so, the eventual money APDN gets, assuming Sabby at some point exercises its warrants, will be less than before a sub $2 new issue. But it will still be signicant new money into the company’s coffers. Plus the new issue money. A nice scenario for Sabby for sure but not that bad for the rest of us.
Do you know how many warrants Sabby currently owns?
With good news and a rising pps, couldn't the company issue shares with attached warrants exercisable above Sabby's magical $2 with no reset effect as Foose postulated in post #53044?
That sounds like reasonable logic. The only scenario that I could see that might be a fly in the ointment is as follows:
During the recent cc, Dr. Hayward indicates that a pp or financing is being delayed even though cash burn will eat up remaining monies very shortly. Perhaps this was done as a calculated risk because he believes the company is on the cusp of a significant announcement even though no agreement has yet been signed (and therefore cannot be publicly announced). Then a future pp could be accomplished at a much higher per share value.
I think the company should canvass for someone with a proven track record of accelerating company growth and product acceptance. The particular industry is likely not as important as the experience. However, investment banking, government relations and/or pharmaceutical experience wouldn't hurt (the larger markets for the company).
Please note how a change was made in the below company:
2018-02-13 07:58 ET - News Release
GRANDE WEST ANNOUNCES LEADERSHIP CHANGES
Grande West Transportation Group Inc. has appointed Jean-Marc Landry to the position of chief executive officer.
Grande West is making leadership changes that are focused on aligning corporate management with the needs of its growing company. These efforts are an important part of the company's shift from a product-focused business to a stronger sales and customer development organization.
Over the course of the past 10 years and William Trainer's leadership, Grande West designed, engineered, manufactured, assembled and delivered its best-in-class mid-sized Vicinity bus. To date, Grande West has delivered over 300 buses in Canada and the United States, and is experiencing increased demand as the concept of rightsizing takes hold.
At this time, to support this change in focus, Grande West announces that Mr. Trainer will transition from his CEO role to undertake the roles and responsibilities of president and remain as a member of the board of directors. Mr. Landry, the company's existing vice-president of sales, will assume the CEO role.
Mr. Trainer notes: "I've been intimately involved with the success of Grande West to date and have been very pleased with our growth and expansion throughout North America. However, there comes a point in time when good corporate governance demands the right people in the right roles. That time has come. Our company is reaching an inflection point in our growth and our next phase along this growth path is focused on sales. So, sales strategy rather than product design strategy moves to the forefront. I feel very comfortable handing the reins over to Jean-Marc."
"Will and I have worked together for over four years now," said Mr. Landry, "and we will continue to work diligently to grow Grande West as we move forward into 2018 and beyond. We will begin to implement expanded sales strategies and processes that will support the continued rapid growth that we expect. I will also be working alongside others here at the company to assure that our shareholders and other stakeholders are well informed of our progress."
Exactly RandyK. We need a salesman/build-out expert with appropriate industry experience and contacts to take us to the next level. There is still a place for Jim Hayward in product development. Just not at the company’s helm.